Ropivacaine Hydrochloride Monohydrate is the salt form of its parent API, engineered to achieve a target aqueous solubility and dissolution profile that ensures consistent oral bioavailability across the patient population. The stoichiometry of API to counter-ion, defined in the salt’s molecular formula, determines the dose equivalent and the appropriate molecular weight correction applied when converting the PDE value to a cleaning validation maximum allowable carryover expressed in mass of salt per unit equipment surface area or per unit rinse volume.
Cleaning validation acceptance criteria for Ropivacaine Hydrochloride Monohydrate in shared pharmaceutical equipment are determined using the health-based MACO formula: MACO (mg/batch) = PDE(mg/day) × MBS(g) ÷ TDD(g/day), where MBS is the minimum batch size of the next product and TDD its maximum daily therapeutic dose.
